Abstract
Knowledge about the pathophysiology of psoriasis has evolved substantially in recent years, since the identification of the T helper 17 (Th17) cells. Cytokines produced by these cells appear to play major roles in psoriatic inflammation. The cytokine interleukin (IL)-23 appears to promote regulatory T cells to differentiate into Th17 cells. Available and investigational therapies act on targets within these pathways.
Original language | English (US) |
---|---|
Journal | Seminars in cutaneous medicine and surgery |
Volume | 35 |
Issue number | 4 S |
DOIs | |
State | Published - 2016 |
Funding
Publication of this CME/CE article was jointly provided by Rutgers, The State University of New Jersey and Global Academy for Medical Education, LLC with Skin Disease Education Foundation (SDEF) and is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.
Keywords
- IL-17
- IL-23
- Psoriasis treatment
- Th17 pathway
ASJC Scopus subject areas
- Surgery
- Dermatology